How much funding has Optonol raised?

Optonol has raised $20.0M in total funding, most recently a Series C round.

Who are Optonol's investors?

Optonol's investors include Pitango Growth.

Where is Optonol headquartered?

Optonol is headquartered in Neve Ilan, Israel.

What industry is Optonol in?

Optonol operates in Healthcare, Medical Devices.

Optonol

Acquired

Miniature glaucoma implants for surgical precision

Neve Ilan, Israel · Founded 1996 · $20.0M raised

Healthcare

Medical Devices

Headquarters: Neve Ilan
Employees: 11–50
Founded: 1996
Business Model: B2B

Website: optonol.com
Total Funding: $20.0M
Last Round: Series CFeb 2009
Rounds: 1

About

Optonol Ltd. was founded in 1996 as a spin-off of Jerusalem-based stent developer Medinol Ltd. The company developed the Ex-PRESS miniature glaucoma implant — a device smaller than a grain of rice made from surgical stainless steel with an internal diameter of 50 or 200 microns. The Ex-PRESS shunt is used in filtering surgery to lower intraocular pressure in glaucoma patients, offering a less invasive alternative to traditional trabeculectomy. Optonol's development center was located in Neve Ilan near Jerusalem, Israel. The company raised over $20 million from investors including Israel Healthcare Ventures and Pitango Venture Capital before being acquired by Alcon in 2010 for an initial payment of $150 million with additional milestone payments.

Summary

Optonol is a Healthcare company based in Neve Ilan, Israel, founded in 1996. It has raised $20.0M in total across 1 round, most recently a Series C round in Feb 2009. Investors include Pitango Growth.